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ABSTRACT: We report on the synergistic effect of PI3K inhibition with ALK inhibition for the possible treatment of EML4-ALK 
positive lung cancer. We have brought together ceritinib (ALK inhibitor) and pictilisib (PI3K inhibitor) into a single bivalent molecule 
(a codrug) with the aim of designing a molecule for slow release drug delivery that targets EML4-ALK positive lung cancer. We 
have joined the 2 drugs through a new, pH-sensitive linker where the resulting codrugs are hydrolytically stable at lower pH (pH 6.4), 
but rapidly cleaved at higher pH (pH 7.4). Compound (19), which was designed for optimal lung retention, demonstrated clean 
liberation of the drug payloads in vitro and represents a novel approach to targeted lung delivery.
Of the non-small cell lung cancers (NSCLCs) 3-7% possess 
chromosomal rearrangements of anaplastic lymphoma kinase 
(ALK).1,2  ALK gene translocations such as EML4-ALK, result-
ing from inversions in the p-arm of chromosome 2, lead to the 
fusion of the echinoderm microtubule-associated protein-like 4 
(EML4) and ALK genes and produce constitutively active ALK 
fusion proteins.3,4 The ALK-EML4 fusion gene5 contains exons 
of ALK that code for the intracellular kinase domain of ALK 
and eight EML4 exons, all of which activate downstream sig-
nals of the Ras/Raf/MEK/ERK1/2, JAK/STAT and PI3K/AKT/ 
mTOR pathways,6 ultimately leading to uncontrolled cell 
growth and thus its oncogenic nature.  
As ALK is required for oncogenic activity, ALK inhibitors, 
such as crizotinib,7,8 have been developed as targeted anti-tu-
mour therapies. Ceritinib 1 9,10 developed by Novartis, has been 
approved by the FDA (April 2014) for patients that have re-
lapsed on crizotinib.11 Similarly to crizotinib, ceritinib initially 
shows promising results. However, patients relapse as re-
sistance rapidly emerges. The situation is similar with alec-
tinib12 and lorlatinib,13 where patients initially respond, how-
ever relapse is inevitable. Current treatments involve taking 
these ALK inhibitors in succession as resistance evolves. 14,15  
Another strategy for overcoming resistance to ALK inhibitors 
is to use upfront combination therapies,16 targeting one or more 
signalling nodes that suppress the survival and emergence of 
resistance.17,18 However, it is unclear which effector is most crit-
ical for EML4-ALK driven cell survival. Drug combinations 
have been shown to slow down the evolution of resistance, as 
drugs in combination simultaneously operate with different 
mechanisms of action, thus reducing the probability of muta-
tions. As the overall goal is to identify a bivalent inhibitor where 
the two drugs are conjugated with a pH-dependent cleavable 
linker (Figure 1), the aim of this work is to identify a drug com-
bination that exhibits synergy in a 1:1 molar ratio. Therefore, 
the drug combinations were tested in a 1:1 molar ratio. 
 
Figure 1. Ceritinib 1, pictilisib 2, and the proposed pH-sensitive 
codrug linking strategy. 
The combination of ceritinib (1) and the pan PI3K inhibitor pic-
tilisib (2)19 was investigated. We initially examined in vitro ac-
tivity adopting 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assays against an isogenic pair of hu-
man lung carcinoma cell lines, A549 and A549 EML4-ALK, 
referred to as ALK- and ALK+ respectively. The A549 cell lines 
used, and their respective known mutations are listed in Table 
1. 
Table 1. Cell lines used in assays 
 
Cell Line EML4-ALK PI3KCA Other Mutations 
A549 - wt CDKN2A, KRAS 
CCL-185IG 
(A549 iso-
genic cell line) 
+ wt CDKN2A, KRAS 
 
In vitro evaluation of pictilisib revealed GI50 values of 1217 nM 
± 85 and 1175 nM ± 141 against ALK- and ALK+ A549 cell 
lines respectively. Ceritinib, showed greater inhibitory activity 
against ALK+ cells than ALK- cells (GI50 values 565 ± 102 and 
845 ± 87 nM respectively; Figure 2). 
 
Figure 2. The concentration-response curves for ceritinib, pic-
tilisib and their combination against the ALK- cell line (A) and 
ALK+ cell line (B). (n=3) The dotted line shows the Tzero value, 
and points below this line indicate that an agent is cytotoxic. 
Growth is represented as percentage viability of the control, which 
has been normalized to 100%, where 0% is the Tzero 
Evaluating synergy using the Webb method20 (Figure 3) 
showed no statistical significance between the observed and ex-
pected effects across all drug concentrations in ALK- cells. 
Conversely, against the ALK+ cell line there was good statisti-
cal significance of synergy at concentrations >500 nM. 
 
Figure 3. Combination study of ceritinib and pictilisib against 
the ALK- (A) and ALK+ (B) cell lines, analyzed by the Webb frac-
tional product method, comparing the expected (additive) effect 
against the observed effect. Where the observed % viability is less 
than the expected, synergy can be assumed. Statistical significance 
was determined by calculation of the p-value using t-tests where: 
*** P = 0.001, ** P = 0.01, * P = 0.05, ns P > 0.05. Error bars 
represent the SEM. 
The Chou and Talalay method for drug combinations analyses, 
based on the median-effect equation 21, 22 is discussed in detail 
in SI. The resulting combination index (CI) theory offer quan-
titative definition of additive (CI=1), antagonistic (CI>1) or 
synergistic (CI<1) effects across a range of drug combinations 
(Table 2). The CIs at a fractional effect (Fa) of 0.5 (effectively 
at the IC50) were found to be 0.72 and 0.37 for the ALK
- and 
ALK+ cell lines respectively. At higher concentration, at a frac-
tional effect of 0.35, the CIs were 0.24 against both the ALK- 
and ALK+ cell lines. The CI plots for both cell lines are shown 
in Figure 4. The synergy observed against the ALK+ cell line is 
greater and observed across a broad range of drug concentra-
tions. Isobolograms at IC50, IC75 and IC90 clearly illustrate syn-
ergistic growth inhibition, with strongest synergy at doses 
achieving higher growth inhibitory effects (Figure 4A and 
4B).23,24 Clearly, synergy between pictilisib and ceritinib is ob-
served against the ALK+ cell line.  
 
 
Figure 4. CI plots generated using the Chou and Talalay method 
for a 1:1 molar ratio of pictilisib and ceritinib against the ALK- cell 
line (A) and the ALK+ cell line (B). A CI at a given fractional effect 
of 1 is an additive effect, >1 is antagonistic and <1 is synergistic. 
(B) and (C) isobolograms generated from the Chou and Talalay 
method IC50, IC75 and IC90. 
Table 2. The parameters used to calculate the combination 
index of combinations against the ALK- (grey) and ALK+ 
cell lines.  
 Combination Index 
Drug m-
value# 
Dm 
Value# 
(Fa) 
25 
(Fa) 
50 
(Fa) 
76 
(Fa) 
96 
Ceritinib 0.76 
(0.07) 
0.85 
(0.09) 
    
Pictilisib 0.72 
(0.09) 
1.22 
(0.09) 
0.95 0.72 0.55 0.35 
Combi-
nation 
0.88 
(0.07) 
0.67 
(0.05) 
    
Ceritinib 0.76 
(0.07) 
0.57 
(0.1) 
    
Pictilisib 0.64 
(0.08) 
1.12 
(0.1) 
0.52 0.37 0.30 0.24 
Combi-
nation 
0.28 
(0.05) 
0.60 
(0.22) 
    
The CI is given as an average of the mutually exclusive and mu-
tually non-exclusive combination indices. # (± SEM) M. 
After observing substantial synergy specifically in ALK+ cells, 
western blot analyses were adopted to explore signal transduc-
tion activation following treatment of cells with pictilisib (500 
nM and ceritinib (500 nM). Figure 5 demonstrates the presence 
of the EML4-ALK fusion protein in lysates prepared from 
ALK+ A549 cells.  The presence of STAT3 protein is evident in 
both A549 populations irrespective of EML4-ALK expression 
(Figure 6A). In contrast, downstream of ALK, activation of the 
JAK-STAT pathway (P-STAT3) is detected exclusively in 
ALK+ cells. Also evident is inhibition of STAT3 signalling fol-
lowing treatment of cells with ceritinib alone, and almost com-
plete abolition of P-STAT3 after treatment of cells with the drug 
combination (Figure 6B).   
 
 
Figure 5. (A) Immunoblot analysis confirming lack of EML4-
ALK in the ALK- cell line. (B) Immunoblot analysis confirming 
the presence of EML4-ALK in the ALK+ cell line. The Concentra-
tion-response curves for 23, ceritinib, pictilisib and their combina-
tion against the ALK- cell line 
 
Figure 6. Immunoblot analysis of total STAT3 (A) and P-STAT3 
(B) against the ALK+ and ALK- cell lines after 24 h treatment of 
pictilisib, ceritinib and their combination. 
 
A further issue associated with ceritinib treatment is adverse 
toxicity where >50% patients in clinical trials experienced ad-
verse events that necessitated a reduction in dose. There are also 
serious side effects observed with pictilisib (diarrhoea, nausea, 
taste alteration, rash, fatigue, itchiness, vomiting and decreased 
appetite) where a suggested daily oral dose is 340 mg.25 With 
these adverse effects, either dose-reduction or localized, topical 
application is desirable. One strategy to achieve such outcomes 
would be delivery via controlled release i.e. in the form of a 
prodrug. Inhalation is an increasingly important delivery ap-
proach for respiratory therapeutics and yet there still remains an 
unmet clinical, commercial and practical need for a 'once-a-day' 
treatment. There has been much debate about the various strat-
egies for the rationalization of agents that exhibit a sustained 
duration of action when applied topically to the lung. 26 Exam-
ples of such approaches are compounds that display a reduction 
in solubility and permeability, where slow dissolution into the 
airways smooth muscle affords the potential for extended lung 
retention.27 In addition, increasing lipophilicity has been shown 
to be an important parameter in delivering compounds with an 
extended duration of action.28, 29 Along with modulation in lip-
ophilicity, it has been shown that the incorporation of a dibasic 
pharmacophore within the compounds, leads to an increase in 
the duration of action of inhaled compounds.30 
With these concepts in mind, we have brought together ceritinib 
and pictilisib into a single bivalent molecule (a codrug)31,32 with 
the aim of designing a molecule for slow release drug delivery 
that could target EML4-ALK positive lung cancer. The codrug 
is designed as a bivalent ligand, sporting a pH-dependent cleav-
able linker which is more hydrolytically stable at lower pH (pH 
6.5 vs pH 7.4). This approach is interesting in that the pH of the 
lung environment is slightly acidic (pH ~6.5 to 6.8) enabling a 
potential lung tissue retention for the biologically inactive 
codrug.  
The piperidine ring on ceritinib and the indazole of pictilisib 
were identified as appropriate synthetic handles for exploration. 
In a codrug model system (5), 4-phenyl piperidine (3) and 5-
bromo indazole (4) were used as drug mimetics. With the inda-
zole as a superior leaving group than the piperidine, this was 
used to form an α-amino amide. The α-amino amide was chosen 
with the hypothesis that the amino group will either aid hydrol-
ysis through anchimeric assistance via hydrogen bonding of the 
non-protected amine to water (pKa ~ 7.08).33 This hypothesis 
forms the basis of the pH-dependent linker (Figure 7). 34 An as-
partic acid analogue was chosen to form part of the linker due 
to the well-known cyclization mechanism of amino acid cleav-
age, which would present itself following hydrolysis of the al-
pha amino amide, releasing pictilisib.  
 
 
Figure 7. The hypothesized cleavage mechanism of the codrug. 
The α-amino group delivers water to the site of hydrolysis by an-
chimeric assistance. This anchimeric assistance can either be hin-
dered or assisted, depending on the pH, as the amino group will 
have a different percentage ionization at differing pH. Following 
the delivery of water and release of pictilisib, the codrug has been 
designed to degrade via a well-known cyclization mechanism, 
 
yielding the anhydride (which is subsequently hydrolyzed to the 
amino acid). This is followed by collapse, eliminating acetaldehyde 
(which disproportionates to acetic acid and ethanol - as seen by 
NMR), carbon dioxide, and ultimately ceritinib. It is known that 
release of acetaldehyde could have inflammatory effects in the lung 
tissue, however this could be alleviated in future work through 
modification of the acetal linker group. 
The concept was investigated through the synthesis of a codrug 
model 5. A kinetic study was performed using a time-course NMR 
method where the time course experiment was run at pH 6.4, 6.8 
and 7.4 and the corresponding half-lives and rate constants calcu-
lated (Table 3 and SI). 
Table 3. Half-lives and rate constants for the release of drug 
mimetics from the codrug model system 5 at a range of pH. 
pH t1/2 (hr) k1 (s
-1) percentage unionized 
6.4 4.64 ± 0.5 0.22 ± 0.003 17.3% 
6.8  0.70 ± 0.11 0.84 ± 0.06 34.4% 
7.4 0.39 ± 0.7 1.37 ± 0.17 67.6% 
 
Immediately it could be seen that as the pH increases the model 
codrug cleaves more rapidly (Table 3). The fact that the rate of 
reaction increases with the percentage unionized is evidence in 
favour of the hypothesis that the α-amino group delivers water 
to the amide carbonyl through anchimeric assistance. After 
proof of concept with the model system, cleavable codrugs (19-
21) were synthesized starting from ceritinib and pictilisib 
(Scheme 1).   
Scheme 1. Synthesis of the codrugs (19-21) 
 
Scheme 1. Reagents and conditions: (i) 1 (1.0 eq.), chloroethyl 
chloroformate (1.1 eq.), NMM (2.0 eq.), CH2Cl2, -10 °C, 45 min; 
(ii) N-boc-Cbz-protected amino acid 7-9 (0.8 eq.), Ag2O, NBu4Br 
(0.16 eq.) , Toluene, 60 °C, overnight, Yield 34-77%; (iii) Pd/C, 
H2, EtOAc, rt, overnight, Yield 76-99%; (iv), 2 (1.0 eq.), HATU 
(1.1 eq.), DIPEA (3.0 eq.), CH2Cl2, rt, 6 hr, Yield 3-11%; (iv) TFA, 
CH2Cl2, rt, 1 hr, 100%. 
The synthesis of codrugs (19-21) started with the acylation of 
ceritinib (1) with 1-chloroethyl chloroformate (ACE-Cl) in the 
presence of N-methyl morpholine to give (6). Coupling of the 
amino acid partners (7-9) was achieved using silver oxide con-
taining a catalytic amount of tert-butyl ammonium bromide in 
toluene at 60 °C. Following deprotection, the corresponding 
carboxylic acids (13-15) were reacted with 2 to give the Boc-
protected codrugs (16-19). Once required, the protecting group 
was removed with TFA to give the codrugs (19-21). The pro-
tected codrugs were stable in air at room temperature >1 year 
after synthesis 
 The hydrolytic stability of (19-21) was investigated in buffered 
solutions supplemented with 4% bovine serum albumin (BSA) 
to aid solubility (Table 4). In addition, rat plasma stability was 
assessed (Table 5). The stability results for (19) at both pH 6.5 
and pH 7.4 (Figure 8) show clean conversion to pictilisib and 
ceritinib. 
 
Figure 8. Release of 19 at (A) pH 6.5 and (B) in pH 7.4 phos-
phate buffer containing 4% BSA showing degradation of the 
codrug with release of pictilisib followed by the subsequent release 
of ceritinib. (C) Stability study of 19 in rat plasma.  
Table 4. Summary of half-lives and rate constants for the 
codrug systems in buffer + 4 % BSA. 
Example pH k/  s-1 t1/2/ h r
2 
19 6.5 0.036 ± 0.01 19.3 0.79 
 7.4 0.094 ± 0.04 7.4 0.70 
20 6.5 0.02 ± 0.03 34.7 0.93 
 7.4 0.036 ± 0.01 19.3 0.74 
21 6.5 0.058 ± 0.03 12.0 0.99 
 7.4 0.091 ± 0.02 7.6 0.87 
The compounds were assayed as a mixture of 2 diastereomers. 
However, 19 was purified by HPLC and it was observed that there 
was no difference in the rates of release of the single enantiomers. 
From Table 4 it can be seen that the half-lives of the codrugs at 
pH 6.5 are longer than the half-lives at pH 7.4..  
In rat plasma, the degradation of 20 is different to that of 19, 
which showed a zero-order degradation (a linear plot of 
[codrug] vs time). Compound 20 shows a first order degradation 
profile.  
Table 5. Summary of rate constants and half-lives for the 
codrug systems in rat plasma 
Example k t1/2/min r
2 Order 
19 0.069 ± 0.02 M s-1 58 0.85 zero 
20 0.018 ± 0.001 s-1 38 0.99 first 
21 0.01 ± 0.001 s-1 69 0.97 first 
 
 
The biological evaluation of 19 was studied by MTT assay, and 
compared to the ceritinib/pictilisib combination (Figure 9). 
  
Figure 9. The concentration-response curves for (19), ceritinib, pic-
tilisib and their combination against the ALK- cell line (A) and 
ALK+ cell line (B). Points represent the means ± SEM (minimum 
3 internal replicates). The dotted line shows the Tzero value, and 
points below this line indicate net cytotoxicity. Growth is repre-
sented as percentage viability of the control, which has been nor-
malized to 100%, where 0% is the Tzero. 
The concentration-response curve in the ALK+ cell line appears 
to mirror the concentration-response of the combination but is 
right shifted. This suggests that the codrug had not fully cleaved 
to provide the drugs in the desired concentration to have the re-
quired biological effect. There most probable reason for this ef-
fect is that the codrug is highly protein bound.  As accumulating 
evidence suggested that FBS negatively impacted biological ac-
tivity, 19 was incubated in RPMI medium containing 10% FBS 
and the drugs’ release was followed by HPLC. Even after 72 h 
the codrug had not released its active payloads and this is highly 
likely a consequence of very high protein binding (Figure 10). 
  
 
Figure 10. Release study of 23 in RPMI cell culture medium con-
taining 10% FBS at 37 oC.  Minimal release of the drugs after 72 h 
indicates binding of the protected codrug to proteins.  
To conclude, we have demonstrated the synergistic biological 
activity between pictilisib and ceritinib and have used this find-
ing to design, synthesize and test a novel codrug system where 
the two drugs are joined by a new pH-cleavable linker. Whilst 
the resulting codrug did not display the anticipated enhanced 
biological response, we have suggested that this is likely be-
cause of the inherent high albumin binding exhibited by the 
codrug due to its high lipophilicity (cLogP 6.9).33 However, we 
postulate that this could be a possible benefit for inhaled sus-
tained delivery applications. Further work is on-going to ex-
plore the albumin binding dependence and cleavage of the 
codrugs and will be reported in due course.  
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